Kiadis Pharma B.V., an Amsterdam, The Netherlands-based clinical stage biopharmaceutical company developing treatments for blood cancers, is to receive an innovation credit of up to €3m from AgentschapNL, a division of the Dutch Ministry of Economic Affairs.
The line will support the Phase II clinical development of Kiadis Pharma’s lead pipeline product, ATIR™.
The company is currently conducting a Phase II international multi-center study with ATIR™, its cell based product for blood cancers, in order to confirm and extend previous Phase I/II results.
Led by Manfred Ruediger, PhD, Chief Executive Officer, Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the development and manufacturing of ATIR™.
The company is backed by international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM.